Feedback / Questions
NNI-362 - NeuroNascent
https://www.globenewswire.com/news-release/2025/08/13/3132372/0/en/Neuronascent-Announces-Progress-for-Lead-Candidate-NNI-362-Publication-of-Phase-1a-Clinical-Trial-Results-and-FDA-Grants-Waiver-of-Fee-for-Canine-Cognitive-Disorder-2025-Submission.html
Aug 13, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next